Hydrophilic linker platform
The efficiency of ADCs as therapeutic agents against cancer relies on several key parameters such as plasmatic stability, Drug-Antibody Ratio (DAR), position of the drug-linker couple on the antibody or overall hydrophobicity. Hydrophobicity has indeed revealed itself to be an important physicochemical parameter, directly influencing ADCs pharmacokinetics. Drugs used for cancer treatments protocols are highly hydrophobic, which prevents from loading numerous molecules on an antibody.
High DAR up to 8-16
No mAb re-engineering - No tedious enzymatic coupling
Our technology is compatible with any IgG without mAb or cell-line re-engineering. No tedious, expensive and time-consuming enzymatic coupling, remodeling steps or two-step coupling procedures are necessary to produce the ADC.
No premature release of the payload
Plasma stable cysteine coupling chemistry prevents premature cleavage and albumin transfer of the cytotoxic payload in the bloodstream, decreases systemic toxicity and improves therapeutic index.